The good, the bad, and the ugly: sodium-glucose cotransporter-2 inhibitors (gliflozins) and perioperative diabetes Among the eight classes of drugs available to control blood sugar in patients with type 2 diabetes, the newest class is the sodium-glucose cotransporter-2 (SGLT2) inhibitors, or 'gliflozins', which includes canagliflozin, dapagliflozin and empagliflozin. These recently introduced medications are widely predicted to become commonly used in type 2 diabetes. There are now concerns of some common, and some rare but serious, hazards that may be associated with these medications in the perioperative setting.
The SGLT2 inhibitors are associated with enhanced blood glucose control as well as a reduction in all-cause mortality, myocardial infarction, heart failure admissions and renal replacement therapy (the good). However, the SGLT2 inhibitors are also associated with increased genital and urinary tract infections (the bad), and a rare, hard to diagnose, and potentially fatal condition (the ugly): euglycaemic diabetic ketoacidosis (euDKA) [1] [2] [3] . In this edition of Anaesthesia and Intensive Care, Chacko and colleagues report two patients who became critically ill with euDKA after surgery 4 . This Australian report adds to a recent letter in Anaesthesia and Intensive Care with a report from the United States 5 and other reports in the international literature [6] [7] [8] [9] . As with other reports, the standout features of the report by Chacko and colleagues are that both patients: 1) were on SGLT2 inhibitors in the perioperative period; 2) had severe postoperative clinical deterioration; 3) had severe acidaemia secondary to marked metabolic acidosis; 4) had a blood glucose <14 mmol/l (euglycaemia); and 5) improved clinically with insulin therapy as part of intensive care treatment.
The SGLT2 inhibitors were first approved in Australia (and the USA) in 2014, with some availability in Europe before this. The sodium-glucose cotransporter-2 (SGLT2) is a protein responsible for reabsorption of glucose from the proximal renal tubule. Inhibiting the transporter protein promotes urinary excretion of glucose, enhancing control of blood glucose in patients with diabetes with minimal risk of hypoglycaemia 10 . The SGLT2 inhibitors are indicated either alone, or in combination with metformin, a sulfonylurea or insulin, for patients with type 2 diabetes to improve glycaemic control. In early 2017, following evidence of decreased cardiovascular death, myocardial infarction, all-cause mortality and hospitalisations for heart failure 11 , the indications were extended to patients with type 2 diabetes mellitus and established cardiovascular disease.
Cardiovascular benefits of SGLT2 inhibitors were also demonstrated with canagliflozin 12 , and the cardiovascular effects of dapagliflozin, in a trial involving 17,000 participants, are anticipated to be published in the near future. Furthermore, both empagliflozin and canagliflozin have renoprotective effects 11, 13 . These combined benefits mean that SGLT2 inhibitors have revolutionised the management of type 2 diabetes in Australia and across the world.
The two drugs currently available on the Pharmaceutical Benefits Scheme (PBS) in Australia are dapagliflozin (Forxiga; AstraZeneca, Macquarie Park, New South Wales) and empagliflozin (Jardiance; Boehringer Ingelheim, North Ryde, New South Wales). Canagliflozin was removed from the Australian market for commercial reasons. All three drugs are currently available in New Zealand. Although the SGLT2 inhibitors currently have restricted PBS subsidy, their use in Australia has grown rapidly, with approximately one million prescriptions in the last financial year (Table 1) . This is also the experience internationally. In the USA, sales of empagliflozin were estimated at US$200 million in 2016 and are expected to exceed US$1 billion annually by 2020. Unsurprisingly, the SGLT2 inhibitors have been described as 'blockbuster drugs' by financial/investment commentators. More than 5% of the Australian population (one million people) have type 2 diabetes. Therefore many patients using these drugs will present for both planned and emergency surgery. As anaesthetists are more likely to come across SGLT2 inhibitors, it is important to understand their full sideeffect profile.
The most frequent important complications associated with the SGLT2 inhibitors are genital and urinary tract infections, possibly secondary to increased glycosuria 15 . The added risk of perioperative infections is unclear, however patients undergoing gynaecologic or urologic surgery and/or who have postoperative urinary catheters may potentially be at further risk. This association alone warrants caution with the Editorial SGLT2 inhibitors in the perioperative period. However, euDKA presents a much greater, but far less common, perioperative threat. In a non-surgical setting, the incidence of euDKA may be around one to five cases per 10,000 patients on an SGLT2 inhibitor per year [16] [17] [18] . However, surgery appears to be a precipitating factor 19, 20 . Adding to the cases in this journal, three cases and an accompanying editorial were published in the Canadian Journal of Anaesthesia in early 2018 describing euDKA in three patients after cardiac surgery 6, 21 . There are some other published case reports [7] [8] [9] . We are aware of other possible cases, as yet unpublished, requiring critical care management. It is timely to consider the increasing number of case reports in more detail, to raise awareness of the problem and to consider appropriate advice regarding perioperative medication management.
The mechanism of euDKA is still unclear 22 .
However physiological stress appears to be a key association, with surgery an identified risk factor. During physiological stress, glycogenolysis is induced by catecholamine and autonomic pathways and (normally) plasma glucose rises, inducing insulin release. In the absence of insulin, glucose remains extracellular and cells switch to ketogenic metabolism, as is seen in classical hyperglycaemic ketoacidosis. Euglycaemic ketoacidosis, in type 1 diabetes with fluid and electrolyte disturbance was described in five patients in 1973 23 , but was an uncommon, perhaps under-recognised physiological oddity. In the presence of SGLT2 inhibitors, there is a relative hypoglycaemia, i.e. plasma glucose is not raised in response to the catecholamine stress due to altered renal glucose handling. This, in turn, attenuates the insulin response and thus facilitates ketoacidosis in the setting of euglycaemia. As noted in the case reports, perioperative euDKA tends to occur after hours to days of the physiological stress associated with surgery, possibly further aggravated by cardiopulmonary bypass. Patients with type 1 diabetes receiving off-label SGLT2 inhibitor therapy, patients with latent autoimmune diabetes of adulthood (LADA) misdiagnosed as type 2 diabetes, and patients with insulin-requiring type 2 diabetes may also be at greater risk of euDKA. These risks may be further increased if SGLT2 inhibitor therapy is either continued through the perioperative period or reintroduced in the early postoperative phase. As described in the case reports, diagnosis may be delayed by apparent normoglycaemia, misdiagnosing compensatory hyperventilation as a respiratory complication, and by general unfamiliarity with the condition 24 . Additionally, DKA may be overlooked or not considered in the differential diagnoses in patients with type 2 diabetes.
The true incidence of euDKA in the perioperative setting is unclear, and there are a number of possible reasons for the increasing number of cases reported: 1. Prescribing of SGLT2 inhibitors has rapidly increased ( 6, 22, [25] [26] [27] . We recommend slightly earlier preoperative cessation, and emphasise that there should be no rush to recommence therapy postoperatively. We will not discuss the critical care management, which is well described in other sources 28 . 1. Awareness of euDKA is the most important change. 2. SGLT2 inhibitor therapies are used to optimise long-term diabetes care and reduce cardiovascular complications. There is no significant danger from temporarily ceasing these drugs, nor any apparent withdrawal syndrome. The recent reports suggest that current recommendations to cease SGLT2 inhibitors on the day of surgery, or the day before surgery, may be inadequate. The drugs should, ideally, be ceased four to five half-lives before surgery. The half-life for both empagliflozin and dapagliflozin is approximately 12 hours. We therefore recommend cessation 48 hours or more before surgery. 3. Pragmatically, patients may arrive for planned surgery without having ceased SGLT2 inhibitor therapy as early as we recommend. Whether to cancel planned surgery is controversial and will need to be based on individual patient circumstances including complexity and duration of surgery. At this time it is not clear how often euDKA occurs, however, we presume that the lower the perioperative physiologic stress, the lower the risk of euDKA. The risk of euDKA can generally be managed with adequate awareness and monitoring, but ongoing SGLT2 inhibitor therapy may be regarded as a relative contraindication to surgery, particularly cardiac surgery and major non-cardiac surgery. 4. Patients having unscheduled and emergency surgery (and who therefore have not ceased these medications), may be at greater risk due to both ongoing SGLT2 inhibitor effects and increased stress from their surgical condition. Furthermore, the exact type of oral diabetes therapy may be unclear when assessing a patient before urgent surgery. Hence there should be increased awareness of the risk of the condition for non-elective patients. 5. Equipment for point-of-care (fingerprick) blood testing for blood glucose and ketonaemia should be used for assessment and monitoring of patients perioperatively. 6. Patients on SGLT2 inhibitors may be mildly volume depleted (like patients on angiotensin converting enzyme and angiotensin II receptor inhibitors). This may lead to increased blood pressure variability, particularly on induction, and may respond to a modest volume load. 7. SGLT2 inhibitor therapy is associated with increased risk of urinary tract and genital infections due to glycosuria. This should be considered, particularly in patients having urogenital procedures. 8. Where a decision is made to proceed with surgery in a patient who has had continuing SGLT2 inhibitor therapy, we recommend the following: a. As with all perioperative medicine, management should be in collaboration with surgeons, experts in diabetes care and intensive care colleagues. b. A plan of care should be documented in the general medical notes preoperatively. The preoperative 'Time-Out' check may be an appropriate time to review this. c. The increased need for postoperative surveillance should be considered. For surgery with higher physiological stress, and patients with other risk factors, postoperative critical care admission should be considered. d. Perioperative insulin and glucose therapy may reduce the risk of euDKA. e. Regular monitoring for ketosis could commence at the time of surgery and significant ketonuria or ketonaemia (>0.6 mmol/l preoperatively, or >1.5 mmol/l postoperatively) should prompt a patient review, including blood gas acid-base estimation. f. Continue monitoring until the physiological stress is resolved or for about 72 hours after cessation of SGLT2 inhibitor therapy. 9. There no need to be hasty in recommencing SGLT2 inhibitor therapy after surgery. Advice to recommence SGLT2 inhibitor therapy 'when eating normally', or that "Treatment may be restarted once the patient's condition has stabilised" 26 may lack caution, particularly when enhanced recovery after surgery (ERAS) protocols emphasise early feeding postoperatively. For moderate or major surgery, the drugs should be withheld until the acute phase response and physiological stress has resolved, the patient is eating and drinking normally and the anabolic phase of physiological recovery is established. As a suggested guide for joint arthroplasty, a week or longer may be appropriate; for major body cavity surgery up to two weeks or longer.
10. When SGLT2 inhibitors are restarted, they should be ceased again if the patient deteriorates. Assessment for metabolic acidosis should be an early step in managing any deterioration. Long-term surveillance and vigilance is warranted with all new drugs to enable a full safety profile to be established. As has been the experience with other drugs, such as the novel anticoagulants, the experience with the introduction of SGLT2 inhibitors demonstrates the need for close communication between those introducing new therapies and those who are responsible for managing patients and their comorbidities.
The SGLT2 inhibitors appear to be a major advance in managing patients with type 2 diabetes, and will become much more widely encountered in the perioperative setting. It is currently unclear how commonly euDKA actually occurs. It is important to monitor and further investigate the true prevalence of DKA in patients with diabetes treated with or without SGLT2 inhibitor therapy. Further, there may still be physiological effects and pharmacological interactions of these drugs that have not been identified. The most useful research would be a national registry to report euDKA with and without SGLT2 inhibitor therapy as a collaboration between critical care specialties and diabetologists.
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